Mariarosa Ab Melone

List of Publications by Year
in descending order

135 papers	3,883 citations	117625 34 h-index	168389 53 g-index
142 all docs	142 docs citations	142 times ranked	6549 citing authors

#	Article	IF	Citations
1	POLR3A variants in hereditary spastic paraparesis and ataxia: clinical, genetic, and neuroradiological findings in a cohort of Italian patients. Neurological Sciences, 2022, 43, 1071-1077.	1.9	8
2	Fighting the Huntingtonâ€™s Disease with a G-Quadruplex-Forming Aptamer Specifically Binding to Mutant Huntingtin Protein: Biophysical Characterization, In Vitro and In Vivo Studies. International Journal of Molecular Sciences, 2022, 23, 4804.	4.1	7
3	Genotype-Phenotype Correlations in Neurofibromatosis Type 1: Identification of Novel and Recurrent NF1 Gene Variants and Correlations with Neurocognitive Phenotype. Genes, 2022, 13, 1130.	2.4	10
4	Antiâ€VEGF DNAâ€based aptamers in cancer therapeutics and diagnostics. Medicinal Research Reviews, 2021, 41, 464-506.	10.5	39
5	Novel autophagic vacuolar myopathies: Phenotype and genotype features. Neuropathology and Applied Neurobiology, 2021, 47, 664-678.	3.2	4
6	Neuroacanthocytosis Syndromes in an Italian Cohort: Clinical Spectrum, High Genetic Variability and Muscle Involvement. Genes, 2021, 12, 344.	2.4	6
7	Rare Variants in Autophagy and Non-Autophagy Genes in Late-Onset Pompe Disease: Suggestions of Their Disease-Modifying Role in Two Italian Families. International Journal of Molecular Sciences, 2021, 22, 3625.	4.1	2
8	â€œOne Healthâ€•Approach for Health Innovation and Active Aging in Campania (Italy). Frontiers in Public Health, 2021, 9, 658959.	2.7	8
9	Quantitative Evaluation of Upright Posture by x-Ray and 3D Stereophotogrammetry with a New Marker Set Protocol in Late Onset Pompe Disease. Journal of Neuromuscular Diseases, 2021, 8, 979-988.	2.6	6
10	Short and long term effects of Nabiximols on balance and walking assessed by 3D-gait analysis in people with Multiple Sclerosis and spasticity.. Multiple Sclerosis and Related Disorders, 2021, 51, 102805.	2.0	15
11	NGS in Hereditary Ataxia: When Rare Becomes Frequent. International Journal of Molecular Sciences, 2021, 22, 8490.	4.1	12
12	Neurofibromatosis type 1: Molecular spectrum of the NF1 mutations in a large cohort of adult Italian patients. Journal of the Neurological Sciences, 2021, 429, 118277.	0.6	0
13	Expression profiling of circulating miRNA in the Neurofibromatosis type 1 and related cancers in a large NF1 Italian cohort. Journal of the Neurological Sciences, 2021, 429, 118276.	0.6	0
14	Nanoparticle-Guided Brain Drug Delivery: Expanding the Therapeutic Approach to Neurodegenerative Diseases. Pharmaceutics, 2021, 13, 1897.	4.5	27
15	Intrafamilial â€œDOAâ€plusâ€•phenotype variability related to different OMI/HTRA2 expression. American Journal of Medical Genetics, Part A, 2020, 182, 176-182.	1.2	2
16	Understanding the Biological Activities of Vitamin D in Type 1 Neurofibromatosis: New Insights into Disease Pathogenesis and Therapeutic Design. Cancers, 2020, 12, 2965.	3.7	12
17	The Discovery of Highly Potent THP Derivatives as OCTN2 Inhibitors: From Structure-Based Virtual Screening to In Vivo Biological Activity. International Journal of Molecular Sciences, 2020, 21, 7431.	4.1	7
18	â€œBorderlineâ€•idiopathic CD4+ T-cell lymphocytopenia presenting with atypical progressive multifocal leukoencephalopathy. Journal of Neuroimmunology, 2020, 349, 577420.	2.3	1

#	Article	IF	Citations
19	Bioactive Phenolic Compounds in the Modulation of Central and Peripheral Nervous System Cancers: Facts and Misdeeds. Cancers, 2020, 12, 454.	3.7	12
20	Increase of circulating IGFBP-4 following genotoxic stress and its implication for senescence. ELife, 2020, 9, .	6.0	22
21	The Autophagy Signaling Pathway: A Potential Multifunctional Therapeutic Target of Curcumin in Neurological and Neuromuscular Diseases. Nutrients, 2019, 11, 1881.	4.1	35
22	Clinical and Genetic Findings in Children with Neurofibromatosis Type 1, Legius Syndrome, and Other Related Neurocutaneous Disorders. Genes, 2019, 10, 580.	2.4	25
23	Senescence Phenomena and Metabolic Alteration in Mesenchymal Stromal Cells from a Mouse Model of Rett Syndrome. International Journal of Molecular Sciences, 2019, 20, 2508.	4.1	11
24	A case of Foixâ€“Chavanyâ€“Marie syndrome due to bilateral corona radiata infarcts. Neurology and Clinical Neuroscience, 2019, 7, 279-281.	0.4	1
25	A rapid, safe, and quantitative in vitro assay for measurement of uracil-DNA glycosylase activity. Journal of Molecular Medicine, 2019, 97, 991-1001.	3.9	5
26	Early posterior vitreous detachment is associated with LAMA5 dominant mutation. Ophthalmic Genetics, 2019, 40, 39-42.	1.2	10
27	Meldonium improves Huntingtonâ€™s disease mitochondrial dysfunction by restoring peroxisome proliferatorâ€activated receptor Î³ coactivator 1Î± expression. Journal of Cellular Physiology, 2019, 234, 9233-9246.	4.1	21
28	Metabolic syndrome, Mediterranean diet, and polyphenols: Evidence and perspectives. Journal of Cellular Physiology, 2019, 234, 5807-5826.	4.1	118
29	Late adult-onset adrenomyeloneuropathy evolving with atypical severe frontal lobe syndrome: Importance of neuroimaging. Radiology Case Reports, 2019, 14, 309-314.	0.6	2
30	The senescence-associated secretory phenotype (SASP) from mesenchymal stromal cells impairs growth of immortalized prostate cells but has no effect on metastatic prostatic cancer cells. Aging, 2019, 11, 5817-5828.	3.1	34
31	Circulating factors present in the sera of naturally skinny people may influence cell commitment and adipocyte differentiation of mesenchymal stromal cells. World Journal of Stem Cells, 2019, 11, 180-195.	2.8	11
32	Filamin B and CD13 are components of senescent secretomes that may be involved in primary (stress) Tj ETQq0 0 0 rgBT /Overlock 10 T	0.6	0
33	Successful long-term therapy with flecainide in a family with paramyotonia congenita. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1232-1234.	1.9	7
34	Huntingtin protein: A new option for fixing the Huntington's disease countdown clock. Neuropharmacology, 2018, 135, 126-138.	4.1	19
35	The role of enhancer of zeste homolog 2: From viral epigenetics to the carcinogenesis of hepatocellular carcinoma. Journal of Cellular Physiology, 2018, 233, 6508-6517.	4.1	19
36	Neural stem cells from a mouse model of Rett syndrome are prone to senescence, show reduced capacity to cope with genotoxic stress, and are impaired in the differentiation process. Experimental and Molecular Medicine, 2018, 50, 1.	7.7	20

#	Article	IF	Citations
37	Verapamil Inhibits Ser202/Thr205 Phosphorylation of Tau by Blocking TXNIP/ROS/p38 MAPK Pathway. Pharmaceutical Research, 2018, 35, 44.	3.5	50
38	The carnitine system and cancer metabolic plasticity. Cell Death and Disease, 2018, 9, 228.	6.3	161
39	Autosomalâ€dominant myopia associated to a novel P4HA2 missense variant and defective collagen hydroxylation. Clinical Genetics, 2018, 93, 982-991.	2.0	21
40	Migraine as possible red flag of PFO presence in suspected demyelinating disease. Journal of the Neurological Sciences, 2018, 390, 222-226.	0.6	5
41	Neurofibromatous neuropathy: An ultrastructural study. Ultrastructural Pathology, 2018, 42, 312-316.	0.9	3
42	Multiple spinal nerve enlargement and <scp>SOS1</scp> mutation: Further evidence of overlap between neurofibromatosis type 1 and Noonan phenotype. Clinical Genetics, 2018, 93, 138-143.	2.0	17
43	Resveratrol protects neuronal-like cells expressing mutant Huntingtin from dopamine toxicity by rescuing ATG4-mediated autophagosome formation. Neurochemistry International, 2018, 117, 174-187.	3.8	71
44	Targeted therapy of human glioblastoma via delivery of a toxin through a peptide directed to cell surface nucleolin. Journal of Cellular Physiology, 2018, 233, 4091-4105.	4.1	19
45	Adultâ€onset brain tumors and neurodegeneration: Are polyphenols protective?. Journal of Cellular Physiology, 2018, 233, 3955-3967.	4.1	34
46	Vacuolated PAS-positive lymphocytes as an hallmark of Pompe disease and other myopathies related to impaired autophagy. Journal of Cellular Physiology, 2018, 233, 5829-5837.	4.1	15
47	Localization of neuroglobin in the brain of R6/2 mouse model of Huntingtonâ€™s disease. Neurological Sciences, 2018, 39, 275-285.	1.9	8
48	Next Generation Molecular Diagnosis of Hereditary Spastic Paraplegias: An Italian Cross-Sectional Study. Frontiers in Neurology, 2018, 9, 981.	2.4	64
49	Neuro-BehÃ§etâ€™s disease presenting as an isolated progressive cognitive and behavioral syndrome. Neurocase, 2018, 24, 238-241.	0.6	2
50	Stress and stem cells: adult Muse cells tolerate extensive genotoxic stimuli better than mesenchymal stromal cells. Oncotarget, 2018, 9, 19328-19341.	1.8	57
51	Nano-delivery systems for encapsulation of dietary polyphenols: An experimental approach for neurodegenerative diseases and brain tumors. Biochemical Pharmacology, 2018, 154, 303-317.	4.4	78
52	Mesenchymal stromal cells from amniotic fluid are less prone to senescence compared to those obtained from bone marrow: An in vitro study. Journal of Cellular Physiology, 2018, 233, 8996-9006.	4.1	37
53	Impact of lysosomal storage disorders on biology of mesenchymal stem cells: Evidences from in vitro silencing of glucocerebrosidase (GBA) and alphaâ€galactosidase A (GLA) enzymes. Journal of Cellular Physiology, 2017, 232, 3454-3467.	4.1	19
54	Alterations in the carnitine cycle in a mouse model of Rett syndrome. Scientific Reports, 2017, 7, 41824.	3.3	26

#	Article	IF	Citations
55	First study on the peptidergic innervation of the brain superior sagittal sinus in humans. Neuropeptides, 2017, 65, 45-55.	2.2	12
56	Huntingtin polyQ Mutation Impairs the 17Î²-Estradiol/Neuroglobin Pathway Devoted to Neuron Survival. Molecular Neurobiology, 2017, 54, 6634-6646.	4.0	23
57	Identification of the first dominant mutation of LAMA5 gene causing a complex multisystem syndrome due to dysfunction of the extracellular matrix. Journal of Medical Genetics, 2017, 54, 710-720.	3.2	35
58	Postural and gait patterns assessed by 3D movement analysis in a late onset Pompe disease sibship. Neuromuscular Disorders, 2017, 27, S162-S163.	0.6	0
59	Synergistic Interplay between Curcumin and Polyphenol-Rich Foods in the Mediterranean Diet: Therapeutic Prospects for Neurofibromatosis 1 Patients. Nutrients, 2017, 9, 783.	4.1	25
60	Diffuse glioblastoma resembling acute hemorrhagic leukoencephalitis. Quantitative Imaging in Medicine and Surgery, 2017, 7, 592-597.	2.0	4
61	Rasagiline for sleep disorders in patients with Parkinson’s disease: a prospective observational study. Neuropsychiatric Disease and Treatment, 2016, Volume 12, 2497-2502.	2.2	11
62	The Role of Cathepsin D in the Pathogenesis of Human Neurodegenerative Disorders. Medicinal Research Reviews, 2016, 36, 845-870.	10.5	109
63	Dopamine exacerbates mutant Huntingtin toxicity via oxidative-mediated inhibition of autophagy in SH-SY5Y neuroblastoma cells: Beneficial effects of anti-oxidant therapeutics. Neurochemistry International, 2016, 101, 132-143.	3.8	24
64	A novel diagnostic method to detect truncated neurofibromin in neurofibromatosis 1. Journal of Neurochemistry, 2015, 135, 1123-1128.	3.9	13
65	Ruta graveolens L. Induces Death of Glioblastoma Cells and Neural Progenitors, but Not of Neurons, via ERK 1/2 and AKT Activation. PLoS ONE, 2015, 10, e0118864.	2.5	37
66	Changes in autophagy, proteasome activity and metabolism to determine a specific signature for acute and chronic senescent mesenchymal stromal cells. Oncotarget, 2015, 6, 39457-39468.	1.8	89
67	Foix-Chavany-Marie syndrome in a 17-year-old female with congenital cytomegalovirus infection. Neuropsychiatric Disease and Treatment, 2014, 10, 2249.	2.2	3
68	Giant thrombosed intracavernous carotid artery aneurysm presenting as Tolosa–Hunt syndrome in a patient harboring a new pathogenic neurofibromatosis type 1 mutation: a case report and review of the literature. Neuropsychiatric Disease and Treatment, 2014, 10, 135.	2.2	10
69	High grade glioblastoma is associated with aberrant expression of ZFP57, a protein involved in gene imprinting, and of CPT1A and CPT1C that regulate fatty acid metabolism. Cancer Biology and Therapy, 2014, 15, 735-741.	3.4	57
70	Silencing of RB1 and RB2/P130 during adipogenesis of bone marrow stromal cells results in dysregulated differentiation. Cell Cycle, 2014, 13, 482-490.	2.6	20
71	Unusual StÃ¼veâ€“Wiedemann syndrome with complete maternal chromosome 5 isodisomy. Annals of Clinical and Translational Neurology, 2014, 1, 926-932.	3.7	14
72	The ADAMTS18 gene is responsible for autosomal recessive early onset severe retinal dystrophy. Orphanet Journal of Rare Diseases, 2013, 8, 16.	2.7	41

#	Article	IF	Citations
73	Adherence to anti-Parkinson drug therapy in the â€œREASONâ€•sample of Italian patients with Parkinsonâ€™s disease: the linguistic validation of the Italian version of the â€œMorisky Medical Adherence scale-8 itemsâ€• Neurological Sciences, 2013, 34, 2015-2022.	1.9	29
74	Reasons driving treatment modification in Parkinson's disease: Results from the cross-sectional phase of the REASON study. Parkinsonism and Related Disorders, 2013, 19, 1130-1135.	2.2	16
75	Phosphodiesterase 10A (PDE10A) localization in the R6/2 mouse model of Huntington's disease. Neurobiology of Disease, 2013, 52, 104-116.	4.4	46
76	Mutant huntingtin regulates EGF receptor fate in non-neuronal cells lacking wild-type protein. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 105-113.	3.8	14
77	Efficient cultivation of neural stem cells with controlled delivery of FGF-2. Stem Cell Research, 2013, 10, 85-94.	0.7	21
78	Systemic Delivery of Recombinant Brain Derived Neurotrophic Factor (BDNF) in the R6/2 Mouse Model of Huntingtonâ€™s Disease. PLoS ONE, 2013, 8, e64037.	2.5	74
79	Reduced expression ofMECP2affects cell commitment and maintenance in neurons by triggering senescence: new perspective for Rett syndrome. Molecular Biology of the Cell, 2012, 23, 1435-1445.	2.1	37
80	A synthetic amino acid substitution of Tyr10 in AÎ² peptide sequence yields a dominant negative variant in amyloidogenesis. Aging Cell, 2012, 11, 530-541.	6.7	8
81	Immunohistochemical localization of receptor for advanced glycation end (RAGE) products in the R6/2 mouse model of Huntington's disease. Brain Research Bulletin, 2012, 87, 350-358.	3.0	32
82	Changes in the expression of extracellular regulated kinase (ERK 1/2) in the R6/2 mouse model of Huntington's disease after phosphodiesterase IV inhibition. Neurobiology of Disease, 2012, 46, 225-233.	4.4	22
83	Controlled delivery of the heparan sulfate/FGFâ€2 complex by a polyelectrolyte scaffold promotes maximal hMSC proliferation and differentiation. Journal of Cellular Biochemistry, 2010, 110, 903-909.	2.6	15
84	RAGEâ€“TXNIP axis is required for S100B-promoted Schwann cell migration, fibronectin expression and cytokine secretion. Journal of Cell Science, 2010, 123, 4332-4339.	2.0	79
85	Genes involved in regulation of stem cell properties: studies on their expression in a small cohort of neuroblastoma patients. Cancer Biology and Therapy, 2009, 8, 1300-1306.	3.4	26
86	Identification of novel mutations in theSLC25A15gene in hyperornithinemia-hyperammonemia-homocitrullinuria (HHH) syndrome: A clinical, molecular, and functional study. Human Mutation, 2009, 30, 741-748.	2.5	57
87	Screening of ARHSP-TCC patients expands the spectrum ofSPG11mutations and includes a large scale gene deletion. Human Mutation, 2009, 30, E500-E519.	2.5	53
88	A novel KIF5A/SPG10 mutation in spastic paraplegia associated with axonal neuropathy. Journal of Neurology, 2008, 255, 1090-1092.	3.6	29
89	RAGE recycles at the plasma membrane in S100B secretory vesicles and promotes Schwann cells morphological changes. Journal of Cellular Physiology, 2008, 217, 60-71.	4.1	61
90	New Targets for Therapy in Polyglutamine (polyQ) Expansion Diseases. Current Drug Therapy, 2008, 3, 177-189.	0.3	6

#	Article	IF	Citations
91	Brg1 chromatin remodeling factor is involved in cell growth arrest, apoptosis and senescence of rat mesenchymal stem cells. Journal of Cell Science, 2007, 120, 2904-2911.	2.0	53
92	G.P.16.02 Muscle tissue engineering: Strategies for repair and regeneration in human degenerative muscle diseases. Neuromuscular Disorders, 2007, 17, 874-875.	0.6	0
93	RB and RB2/P130 genes cooperate with extrinsic signals to promote differentiation of rat neural stem cells. Molecular and Cellular Neurosciences, 2007, 34, 299-309.	2.2	15
94	Neurofibromatosis type 1 and optic pathway glioma. A long-term follow-up. Minerva Pediatrica, 2007, 59, 13-21.	2.7	4
95	Spastic paraplegia with thin corpus callosum: description of 20 new families, refinement of the SPG11 locus, candidate gene analysis and evidence of genetic heterogeneity. Neurogenetics, 2006, 7, 149-156.	1.4	43
96	RB and RB2/p130 genes demonstrate both specific and overlapping functions during the early steps of in vitro neural differentiation of marrow stromal stem cells. Cell Death and Differentiation, 2005, 12, 65-77.	11.2	27
97	tBid induces alterations of mitochondrial fatty acid oxidation flux by malonyl-CoA-independent inhibition of carnitine palmitoyltransferase-1. Cell Death and Differentiation, 2005, 12, 603-613.	11.2	57
98	Molecular pathways involved in neural in vitro differentiation of marrow stromal stem cells. Journal of Cellular Biochemistry, 2005, 94, 645-655.	2.6	106
99	Differential carnitine/acylcarnitine translocase expression defines distinct metabolic signatures in skeletal muscle cells. Journal of Cellular Physiology, 2005, 203, 439-446.	4.1	10
100	Autosomal dominant hereditary spastic paraplegia: DHPLC-based mutation analysis ofSPG4 reveals eleven novel mutations. Human Mutation, 2005, 25, 506-506.	2.5	45
101	Huntingtons Disease: New Frontiers for Molecular and Cell Therapy. Current Drug Targets, 2005, 6, 43-56.	2.1	48
102	Neuroacanthocytosis: new developments in a neglected group of dementing disorders. Journal of the Neurological Sciences, 2005, 229-230, 171-186.	0.6	77
103	Revelation of a New Mitochondrial DNA Mutation (G12147A) in a MELAS/MERFF Phenotype. Archives of Neurology, 2004, 61, 269.	4.5	77
104	Role of RB and RB2/P130 genes in marrow stromal stem cells plasticity. Journal of Cellular Physiology, 2004, 200, 201-212.	4.1	20
105	Skeletal muscle metabolism in physiology and in cancer disease. Journal of Cellular Biochemistry, 2003, 90, 170-186.	2.6	61
106	EGFâ€responsive rat neural stem cells: Molecular followâ€up of neuron and astrocyte differentiation in vitro. Journal of Cellular Physiology, 2003, 195, 220-233.	4.1	42
107	Abnormal Accumulation of tTGase Products in Muscle and Erythrocytes of Chorea-Acanthocytosis Patients. Journal of Neuropathology and Experimental Neurology, 2002, 61, 841-848.	1.7	16
108	Decreased mitochondrial carnitine translocase in skeletal muscles impairs utilization of fatty acids in insulin-resistant patients. Frontiers in Bioscience - Landmark, 2002, 7, a109-116.	3.0	22

#	Article	IF	Citations
109	pRb2/p130 Gene Overexpression Induces Astrocyte Differentiation. Molecular and Cellular Neurosciences, 2001, 17, 415-425.	2.2	17
110	RB2/p130 ectopic gene expression in neuroblastoma stem cells: evidence of cell-fate restriction and induction of differentiation. Biochemical Journal, 2001, 360, 569.	3.7	6
111	RB2/p130 ectopic gene expression in neuroblastoma stem cells: evidence of cell-fate restriction and induction of differentiation. Biochemical Journal, 2001, 360, 569-577.	3.7	14
112	17-B estradiol elicits an autocrine leiomyoma cell proliferation: Evidence for a stimulation of protein kinase-dependent pathway. Journal of Cellular Physiology, 2001, 186, 414-424.	4.1	78
113	Carnitine protects the molecular chaperone activity of lens Î±â€crystallin and decreases the posttranslational protein modifications induced by oxidative stress. FASEB Journal, 2001, 15, 1604-1606.	0.5	26
114	Defective growth in vitro of Duchenne muscular dystrophy myoblasts: The molecular and biochemical basis. Journal of Cellular Biochemistry, 2000, 76, 118-132.	2.6	44
115	Induction of apoptosis in ovarian carcinoma cells by AHPN/CD437 is mediated by retinoic acid receptors. Journal of Cellular Physiology, 2000, 185, 61-67.	4.1	44
116	Increased expression of IGF-binding protein-5 in Duchenne Muscular Dystrophy (DMD) fibroblasts correlates with the fibroblast-induced downregulation of DMD myoblast growth: An in vitro analysis. Journal of Cellular Physiology, 2000, 185, 143-153.	4.1	35
117	Defective growth in vitro of Duchenne muscular dystrophy myoblasts: The molecular and biochemical basis. Journal of Cellular Biochemistry, 2000, 76, 118-132.	2.6	18
118	Modulation of in vitro myogenesis induced by different polymer substrates. Journal of Materials Science: Materials in Medicine, 1999, 10, 595-600.	3.6	5
119	Differentiation and apoptosis of neuroblastoma cells: Role of N-myc gene product. , 1999, 73, 97-105.		72
120	Antisense inhibitory effect: A comparison between 3?-partial and full phosphorothioate antisense oligonucleotides. , 1999, 74, 31-37.		24
121	Induction of apoptosis and differentiation in neuroblastoma and astrocytoma cells by the overexpression of Bin1, a novel myc interacting protein. , 1999, 74, 313-322.		43
122	Tissue Transglutaminase-Catalyzed Formation of High-Molecular-Weight Aggregatesin Vitrols Favored with Long Polyglutamine Domains: A Possible Mechanism Contributing to CAG-Triplet Diseases. Archives of Biochemistry and Biophysics, 1998, 352, 314-321.	3.0	114
123	Antisense Oligonucleotides and Myotonin Gene Expression in C2 Mouse Cells. Oligonucleotides, 1998, 8, 25-33.	4.3	2
124	MRI "fogging" in cerebellar ischaemia: case report. Neuroradiology, 1997, 39, 785-787.	2.2	29
125	The differential effects of poly(2-hydroxyethyl methacrylate) and poly(2-hydroxyethyl methacrylate)/ poly(caprolactone) polymers on cell proliferation and collagen synthesis by human lung fibroblasts. , 1997, 34, 327-336.		37
126	Myotonic Dystrophy: Antisense Oligonucleotide Inhibition of DMPK Gene Expressionin Vitro. Biochemical and Biophysical Research Communications, 1996, 221, 750-754.	2.1	19

#	Article	IF	Citations
127	Modulation of cytokine production in activated human monocytes by somatostatin. Neuropeptides, 1996, 30, 443-451.	2.2	68
128	Cell-biomaterial interactions: role of transglutaminase enzyme. Journal of Materials Science: Materials in Medicine, 1996, 7, 707-711.	3.6	2
129	Functional and structural recovery of myotubes from mice with muscular dysgenesis after co-culture with normal, non-myoblastic cells. Biology of the Cell, 1995, 83, 135-140.	2.0	0
130	Regenerated EDL muscle of rats requires innervation to maintain AChE molecular forms. Muscle and Nerve, 1990, 13, 713-721.	2.2	1
131	Effects of glycyl-L-glutamine in vitro on the molecular forms of acetylcholinesterase in the preganglionically denervated superior cervical ganglion of the cat.. Proceedings of the National Academy of Sciences of the United States of America, 1988, 85, 1686-1690.	7.1	11
132	Distributions of molecular forms of acetylcholinesterase and butyrylcholinesterase in nervous tissue of the cat.. Proceedings of the National Academy of Sciences of the United States of America, 1987, 84, 7749-7752.	7.1	18
133	Acetylcholinesterase in neuroblastoma and neuroblastoma Ã— glioma hybrid cells: Cellular localization and molecular forms. International Journal of Developmental Neuroscience, 1987, 5, 417-423.	1.6	11
134	Phenotype heterogeneity among hemizygotes in a family biochemically screened for adrenoleukodystrophy. American Journal of Medical Genetics Part A, 1987, 26, 833-838.	2.4	5
135	Establishment of Neuromuscular Contacts in Cultures of Rat Embryonic Cells: Effect of Tetrodotoxin on Maturation of Muscle Fibers and on Formation and Maintenance of Acetylcholinesterase and Acetylcholine Receptor Clusters. Developmental Neuroscience, 1982, 5, 314-325.	2.0	18